Trial Profile
Drug Use Investigation for TYKERB Tablet (All Case Investigation)
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Jan 2024
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary)
- Indications Advanced breast cancer
- Focus Adverse reactions
- Sponsors GlaxoSmithKline; Novartis
- 25 Apr 2017 Status changed from active, no longer recruiting to completed.
- 17 Nov 2016 Planned End Date changed from 1 Nov 2016 to 1 Apr 2017.
- 17 Nov 2016 Planned primary completion date changed from 1 Nov 2016 to 1 Apr 2017.